濮阳大型工业吸尘器广州工业吸尘器,江门大功率工业吸尘器,益阳大功率工业吸尘器,河北大型工业吸尘器,信阳工业吸尘器厂家,梧州大功率工业吸尘器,厦门工业吸尘器厂家

BERLIN, June 6 (Xinhua) -- The German authorities said on Monday that Germany's first sample tests of the allegedly contaminated bean sprouts have found no E. coli strains that have sickened more than 2,000 people in Europe.According to a statement issued by the Agriculture Ministry of the Lower-Saxony state, 23 of 40 samples concerning the suspected sprouts from a market garden in the state have tested negative, and further tests are still pending."Based on the initial findings in tests of some of the samples, especially the seeds, we assume that intensive analytical efforts are needed to prove that the suspected pathogen is really there," the statement said.Beansprouts and salad sprouts are seen in this picture illustration taken in Berlin June 6, 2011.  The German authorities said on Monday that Germany's first sample tests of the allegedly contaminated bean sprouts have found no E. coli strains that have sickened more than 2,000 people in EuropeLower-Saxony's Agriculture Minister Gert Lindemann said Sunday that a market garden in the rural district of Uelzen had provided a connection "involving all the main outbreaks" of the disease.Restaurants and food outlets of almost all E. coli-affected areas had received shipments of sprouts directly or indirectly from the company, state officials said.The German authorities have been racing to track down the source of the pathogen since the outbreak, which has infected people in 12 countries, all of whom had once traveled in northern Germany.More than 600 of those infected have developed Hemolytic Uremic Syndrome, a potentially deadly complication attacking the kidneys.The E. coli source was first thought to be cucumbers from Spain, which has caused huge loses for Spain farmers. However, this conclusion was overthrown by laboratory tests in Hamburg later.

RAMALLAH, Aug. 26 (Xinhua) -- China's special envoy to the Middle East, Wu Sike, said here Friday that his country fully supports the Palestinians' right to establish an independent state in a balanced manner and through peace talks."China supports the Palestinian people and their cause. We also support the Palestinians to get the United Nations recognition of a Palestinian state on the lands occupied in 1967 with Jerusalem as capital," he told Xinhua in Ramallah.The envoy said peace talks with Israel are the best way to reach a settlement, adding that gaining UN recognition is not an alternative to peace negotiations.China supports a two-state solution -- Israel and an independent Palestinian state living side-by-side in peace and security, he said, noting that he believes the current developments in the Middle East have a positive impact on the Palestinian cause."The Middle East witnesses many changes. People have many chances to participate in political life. The Palestinian cause is a main issue that attracts the attention of the Arab people," he said."The recent meeting of the Arab League Peace Initiative Follow- Up Committee in Qatar assures the Arabs' support to the Palestinians' bid for full UN membership," he said. "This will help the Palestinians gain more international support."The Palestinians say they will approach the UN in September to get full membership of the world body as peace talks with Israel have long been deadlocked, a move disapproved by Israel and the United States.Wu expressed his appreciation of the reconciliation deal signed between Palestinian National Authority President Mahmoud Abbas' Fatah party and Hamas movements in Cairo in May."This move will help the Palestinians to have more countries on their side," he said.Wu said his Middle East tour was taking place at an important moment as the region is witnessing crucial changes, stressing that China respects the choices of the peoples."The Arab peoples are able to make their own decisions toward development," said the envoy.He also said the ties between China and the Arab countries are based on strong foundations, regardless of the changes taking place in the region.Wu met with Palestinian President Mahmoud Abbas and other officials Tuesday, the first day of his ongoing Middle East tour.This was Wu's second visit to Palestinian territories this year, after which he will travel on to Israel, Egypt and France.

RIO DE JANEIRO, Aug. 31 (Xinhua) -- The Brazilian city of Rio de Janeiroe may have an unprecedented dengue fever epidemic next summer, its mayor warned on Wednesday.The increasing number of dengue fever cases in the past few months shows similarities to the months predecing the 2002 and 2008 epidemics, Mayor Eduardo Paes said."Everything points to a new cycle of the disease, certainly the worst epidemic in Rio's history," he said.In 2008, Rio registered some 250,000 cases of dengue fever, with 174 people confirmed dead from the disease. In 2002, Rio had some 290,000 dengue fever cases and 91 people died.In efforts to halt the spread of the disease, Paes has declared a state of alert and is determined to take a series of measures to eliminate the habitat of the Aedes aegypti mosquito, which transmits dengue fever through its bite.Paes also announced an increase in the number of health care units for dengue fever patients. The total cost of a dengue prevention and combat program, which is expected to last until April 2012, will reach 42 million reais (26.25 million U.S. dollars).There is no vaccine against dengue fever, but Brazilian scientists are currently working on one which will immunize against four types of the disease.

BEIJING, July 20 (Xinhuanet) -- Some U.S. soldiers returning from the Middle East have acquired constrictive bronchiolitis, a kind of lung damage virtually unknown in young adults, according to U.S. News & World Report."Respiratory disorders are emerging as a major consequence of service in southwest Asia," said study author Dr. Matthew S. King, an assistant professor of pulmonary and critical care at Meharry Medical College in Nashville, Tenn."In addition to our study, there have been studies showing increases in asthma, obstructive lung disease, allergic rhinitis and a general increase in reports of respiratory symptoms," he added. "Most of the patients say they can’t seem to catch their breath when exerting themselves."On the other hand, Anthony Szema, a physician and engineer at Stony Brook University in New York, has examined a soldier and found tiny complexes of titanium and iron in the man’s lungs, where metals can cause severe damage.Mined separately, the two metals could have gotten together only through a manufacturing process, Szema reported. While the metals’ origin is unclear, he presents a new case study, suspecting garbage-burning pits or exploding devices sent them airborne.While the cases in the study represent only a few dozen people of the hundreds of thousands serving in the Middle East, there is no estimate of how many more might have bronchiolitis.it is recommended that soldiers exercise caution in the field until more is known. Soldiers are now told to wear a mask when burning garbage.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.